Skip to content

Evaluation of safety of cosmetic product

The objective of this study is to evaluate the irritation potential on healthy human subjects of Skin Care Formulation coded

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044281
Enrollment
24
Registered
2022-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Chakramarda Tail (TLS/CMT/22/01): 40 microliters of product is dispensed on aluminium finn chambers and then be taped onto the back of subjects at T1 visit. This is a single applicatio

Sponsors

Transformative Learning Solution Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female and male Asian Indian subjects. 2. Healthy Human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup). 3. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scarâ?¦.) 4. Photo type III to V. 5. Having apparently healthy skin on Test area. 6. For whom the Investigator considers that the compliance will be correct. 7. Cooperating informed of the need and duration of the examination and ready to comply with protocol procedures. 8. Having signed a consent form. 9. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study. 10. Willingness to avoid excessive water contact (for example swimming) or activity which causes excessive sweating (that is exercise saunaâ?¦) during the course of the study. 11. Should be able to read and write in English Hindi or local language. 12. Having valid proof of identity and age.

Exclusion criteria

Exclusion criteria: 1. For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2. Having refused to give his/her assent by not signing the consent form 3. Taking part in another study liable to interfere with this study 4. Being diabetic. 5. Being asthmatic. 6. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). 7. Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin). 8. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 9. Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months. 10. Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit. 11. The day of the patch application: no cosmetic product must be used (test site clean with water only). 12. Scars excessive terminal hair or tattoo on the studied area. 13. Henna tattoo anywhere on the body (in case of studies involving hair dyes). 14. Dermatological infection pathology on the level of studied area. 15. Hypersensitivity & allergy to any cosmetic product raw material or hair dye. 16. Any clinical significant systematic or cutaneous disease which may interfere with the study treatment or procedure. 17. Chronic illness which may influence the outcome of this study. 18. Subjects on any medical treatment either systematic or topical which may interfere with the performance of the study treatment presently or in the past one month. 19. Subject in an exclusion. Or participating in another food cosmetic or therapeutic trial. 20. Refusing to follow the restrictions below during the study: - For female: Do not become pregnant nor breastfeed - Do not take part in another study liable to interfere with this study - Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). - Do not change his/her cosmetic habit so yeah s apart from the particular conditions mentioned in the protocol, on the studied anatomic unit

Design outcomes

Primary

MeasureTime frame
Dermatological safety / Irritation potential on skinTimepoint: 24 hrs after patch removal and T9 days (1 week after 0 hour of patch removal)

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactMr Mohit Lalvani

Transformative Learning Solution Pvt. Ltd.

satyendra.kumar@transformative.in9891253516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026